Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy

Trials

Volumn 14, Issue 1, 2013, Pages

  Na, Ki Young ^a,b   Kim, Dong Ki ^b,c   Kim, Sung Gyun ^d   Lee, Young Ki ^e   Lim, Chun Soo ^b,f  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Hallym University Sacred Heart Hospital   (South Korea)

^e Kangnam Sacred Heart Hospital   (South Korea)

^f Seoul National University Boramae Hospital   (South Korea)

Author keywords

Arterial stiffness; Beraprost sodium; Cardiovascular; Diabetic nephropathy; Pulse wave velocity

Indexed keywords

ALBUMIN; BERAPROST; BIOLOGICAL MARKER; CREATININE; HEMOGLOBIN A1C; PLACEBO;

ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; LABORATORY DIAGNOSIS; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MICROALBUMINURIA; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANKLE BRACHIAL INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; EPOPROSTENOL; HUMANS; PROSPECTIVE STUDIES; PULSE WAVE ANALYSIS; REPUBLIC OF KOREA; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS; VASODILATOR AGENTS;

EID: 84883152070     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-275     Document Type: Article

References (22)

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Guo H, Gustafson S, Heubner B, Lamb K, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, et al. United States renal data system 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis 2012, 59(Suppl 1):e1-e420.
2. Jin DC, Ha IS, Kim NH, Lee SW, Lee JS, Yoon SR, Kim BS. Brief report: renal replacement therapy in Korea, 2010. Kidney Res Clin Pract 2012, 31:62-71.
3. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591. 10.1056/NEJMoa0706245, 18256393.
4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393. 10.1056/NEJMoa021778, 12556541.
5. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999, 353:617-622. 10.1016/S0140-6736(98)07368-1, 10030326.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305. 10.1056/NEJMoa041031, 15385656.
7. Rubin MF, Rosas SE, Chirinos JA, Townsend RR. Surrogate markers of cardiovascular disease in CKD: what's under the hood?. Am J Kidney Dis 2011, 57:488-497. 10.1053/j.ajkd.2010.08.030, 21168944.
8. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999, 99:2434-2439. 10.1161/01.CIR.99.18.2434, 10318666.
9. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T, Nishizawa Y. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001, 12:2117-2124.
10. Mohler ER. Peripheral arterial disease: identification and implications. Arch Intern Med 2003, 163:2306-2314. 10.1001/archinte.163.19.2306, 14581250.
11. Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002, 62:107-133. 10.2165/00003495-200262010-00005, 11790158.
12. Sugawara A, Kudo M, Saito A, Matsuda K, Uruno A, Ito S. Novel effects of beraprost sodium on vasculatures. Int Angiol 2010, 29:28-32.
13. Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism 2003, 52:192-198. 10.1053/meta.2003.50025, 12601631.
14. Nakayama T, Hironaga T, Ishima H, Maruyama T, Masubuchi Y, Kokubun S. The prostacyclin analogue beraprost sodium prevents development of arterial stiffness in elderly patients with cerebral infarction. Prostaglandins Leukot Essent Fatty Acids 2004, 70:491-494. 10.1016/j.plefa.2003.10.004, 15120711.
15. Nakayama T, Masubuchi Y, Kawauchi K, Masaki R, Hironaga T, Ishima H, Torigoe M, Shimabukuro H. Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction. Prostaglandins Leukot Essent Fatty Acids 2007, 76:309-314. 10.1016/j.plefa.2007.05.004, 17616452.
16. Watanabe M, Nakashima H, Ito K, Miyake K, Saito T. Improvement of dyslipidemia in OLETF rats by the prostaglandin I(2) analog beraprost sodium. Prostaglandins Other Lipid Mediat 2010, 93:14-19. 10.1016/j.prostaglandins.2010.04.003, 20450981.
17. Sato N, Kaneko M, Tamura M, Kurumatani H. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes 2010, 59:1092-1100. 10.2337/db09-1432, 2844818, 20068136.
18. Shin S, Kim KJ, Chang HJ, Lee BW, Yang WI, Cha BS, Choi D. The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial. Diabetes Obes Metab 2013, 15:185-188. 10.1111/dom.12010, 22974254.
19. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, . Chronic Kidney Disease Epidemiology Collaboration Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254. 10.7326/0003-4819-145-4-200608150-00004, 16908915, Chronic Kidney Disease Epidemiology Collaboration.
20. Noordzij M, Tripepi G, Dekker FW, Zoccali C, Tanck MW, Jager KJ. Sample size calculations: basic principles and common pitfalls. Nephrol Dial Transplant 2010, 25:1388-1393. 10.1093/ndt/gfp732, 20067907.
21. Mohler ER, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003, 41:1679-1686. 10.1016/S0735-1097(03)00299-7, 12767646.
22. Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G, . Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002, 39:1496-1502. 10.1016/S0735-1097(02)01786-2, 11985913, Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group.